S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis
Laura W J van der Meulen, Menthe E Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L de Kam, Alexa J Tibboel, Thorsten Brach, Bjorn L Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B A van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk · 2026
Read S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis by Laura W J van der Meulen, Menthe E Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L de Kam, Alexa J Tibboel, Thorsten Brach, Bjorn L Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B A van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13619052.txt.
Description
Laura W. J. van der Meulen and thirteen colleagues report the first trial of XZ.700, a lab-made endolysin cream designed to kill Staphylococcus aureus on eczema skin, in a 2026 randomized study. Atopic dermatitis involves microbe imbalance with staph overgrowth. A precision antibacterial could calm symptoms without steroids. Thirty-five patients completed the trial, testing three strengths on clear skin and lesions, then the top strength on lesions for two weeks.
The cream was tolerated, though local reactions occurred and one hypersensitivity reaction made a participant stop. On effect, the verdict was flat: the strongest dose did not reduce staph counts or eczema severity scores. Nor did it cut the bacterium's relative share of the skin microbiome compared with the vehicle. The authors state that XZ.700 showed neither target engagement nor clinical benefit under the conditions tested. The clean negative result redirects the endolysin concept back to formulation questions.
Catalog record
| CREATOR | Laura W J van der Meulen, Menthe E Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L de Kam, Alexa J Tibboel, Thorsten Brach, Bjorn L Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B A van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40822 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |